The Independent [1] |
Immunotherapy for Type 1 Diabetes Deemed Safe in First U.S. Trial [2]
Newswise (press release) Newswise — In the first U.S. safety trial of a new form of immunotherapy for type 1 diabetes (T1D), led by UC San Francisco scientists and physicians, patients experienced no serious adverse reactions after receiving infusions of as many as 2.6 … Purdue researchers develop products and processes to improve detection … [3]News-Medical.net all 15 news articles » [4] |
More details can be found at www.diabeteshowto.com [5]